Abstract | BACKGROUND: METHODS: RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin- ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin- ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P=0.016). Rates of prespecified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit. (Funded by Merck; IMPROVE-IT ClinicalTrials.gov number, NCT00202878.).
|
Authors | Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema, Gaetano M De Ferrari, Witold Ruzyllo, Paul De Lucca, KyungAh Im, Erin A Bohula, Craig Reist, Stephen D Wiviott, Andrew M Tershakovec, Thomas A Musliner, Eugene Braunwald, Robert M Califf, IMPROVE-IT Investigators |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 372
Issue 25
Pg. 2387-97
(Jun 18 2015)
ISSN: 1533-4406 [Electronic] United States |
PMID | 26039521
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticholesteremic Agents
- Azetidines
- Cholesterol, LDL
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Triglycerides
- Simvastatin
- Ezetimibe
|
Topics |
- Acute Coronary Syndrome
(drug therapy)
- Aged
- Anticholesteremic Agents
(adverse effects, therapeutic use)
- Azetidines
(adverse effects, therapeutic use)
- Cardiovascular Diseases
(epidemiology, mortality, prevention & control)
- Cholesterol, LDL
(blood)
- Double-Blind Method
- Drug Therapy, Combination
- Ezetimibe
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(adverse effects, therapeutic use)
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Simvastatin
(therapeutic use)
- Triglycerides
(blood)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|